Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCP-020 Phototoxicity Study
NCT03473184Phase 1Completed
- Sponsor
- Castle Creek Biosciences
- Start
- Dec 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of AC-203 in epidermolysis bullosa simplex (EBS), sponsored by Castle Creek Biosciences. Primary endpoint: Observed Phototoxicity at Day 4. Started Dec 2017; status: completed.
02
Drugs
AC-203
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on NCT03473184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473184.